Local Institution

Stanford, California 94305

0 studies enrolling now · 11 studies all time

What they study most

Bipolar Disorder, Bladder Cancer, Bladder Neoplasms, Blast Crisis, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Kidney Neoplasms, Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive, Neoplasm, Bladder, Philadelphia-Positive Myeloid Leukemia, Scleroderma

Studies at this site

• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) — Withdrawn before enrolling
• Study of Aripiprazole in Patients With a History of Bipolar Disorder — Completed
• Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder — Completed
• Aripiprazole in Children and Adolescents With Bipolar I Disorder — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early